A Phase I clinical trial has recently been initiated to study the preliminary efficacy and safety of universal allogeneic CD19/BCMA CAR-T cell therapy in patients with relapsing/refractory autoimmune diseases, including SSc (NCT06941129). The gene discussed is CD19; the disease is autoimmune disease.